SELLAS Life Sciences Group (SLS) Competitors

SELLAS Life Sciences Group logo
$7.47 -0.39 (-4.96%)
Closing price 04:00 PM Eastern
Extended Trading
$7.95 +0.48 (+6.43%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SLS vs. ORKA, IONS, GRAL, MIRM, and LGND

Should you buy SELLAS Life Sciences Group stock or one of its competitors? SELLAS Life Sciences Group's main competitors and comparable companies include Oruka Therapeutics (ORKA), Ionis Pharmaceuticals (IONS), GRAIL (GRAL), Mirum Pharmaceuticals (MIRM), and Ligand Pharmaceuticals (LGND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SELLAS Life Sciences Group compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.73, meaning that its share price is 173% more volatile than the broader market.

Oruka Therapeutics currently has a consensus price target of $141.80, suggesting a potential upside of 34.60%. SELLAS Life Sciences Group has a consensus price target of $10.00, suggesting a potential upside of 27.23%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Oruka Therapeutics is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oruka Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Oruka Therapeutics' return on equity of -19.34% beat SELLAS Life Sciences Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Oruka TherapeuticsN/A -19.34% -18.74%
SELLAS Life Sciences Group N/A -31.95%-29.86%

Oruka Therapeutics is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oruka TherapeuticsN/AN/A-$105.43M-$2.11N/A
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by company insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Oruka Therapeutics had 19 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 28 mentions for Oruka Therapeutics and 9 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.62 beat Oruka Therapeutics' score of 0.02 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oruka Therapeutics
7 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
SELLAS Life Sciences Group
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Oruka Therapeutics beats SELLAS Life Sciences Group on 8 of the 13 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Ionis Pharmaceuticals?

SELLAS Life Sciences Group (NASDAQ:SLS) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

SELLAS Life Sciences Group has a beta of 2.73, suggesting that its share price is 173% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

SELLAS Life Sciences Group has higher earnings, but lower revenue than Ionis Pharmaceuticals. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A
Ionis Pharmaceuticals$944M5.13-$381.39M-$3.32N/A

SELLAS Life Sciences Group currently has a consensus target price of $10.00, indicating a potential upside of 27.23%. Ionis Pharmaceuticals has a consensus target price of $75.71, indicating a potential upside of 160.54%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Ionis Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.78

In the previous week, Ionis Pharmaceuticals had 46 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 55 mentions for Ionis Pharmaceuticals and 9 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.62 beat Ionis Pharmaceuticals' score of 0.07 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SELLAS Life Sciences Group
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ionis Pharmaceuticals
7 Very Positive mention(s)
6 Positive mention(s)
20 Neutral mention(s)
11 Negative mention(s)
2 Very Negative mention(s)
Neutral

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

SELLAS Life Sciences Group has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -56.98%. SELLAS Life Sciences Group's return on equity of -31.95% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -31.95% -29.86%
Ionis Pharmaceuticals -56.98%-120.62%-16.99%

Summary

Ionis Pharmaceuticals beats SELLAS Life Sciences Group on 9 of the 15 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to GRAIL?

SELLAS Life Sciences Group (NASDAQ:SLS) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 1.8% of GRAIL shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

SELLAS Life Sciences Group has a net margin of 0.00% compared to GRAIL's net margin of -243.80%. GRAIL's return on equity of -16.13% beat SELLAS Life Sciences Group's return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -31.95% -29.86%
GRAIL -243.80%-16.13%-14.38%

SELLAS Life Sciences Group has a beta of 2.73, meaning that its stock price is 173% more volatile than the broader market. Comparatively, GRAIL has a beta of 2.86, meaning that its stock price is 186% more volatile than the broader market.

SELLAS Life Sciences Group presently has a consensus price target of $10.00, suggesting a potential upside of 27.23%. GRAIL has a consensus price target of $128.80, suggesting a potential upside of 11.14%. Given SELLAS Life Sciences Group's higher possible upside, equities analysts clearly believe SELLAS Life Sciences Group is more favorable than GRAIL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
GRAIL
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33

SELLAS Life Sciences Group has higher earnings, but lower revenue than GRAIL. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A
GRAIL$166.60M31.28-$408.35M-$9.50N/A

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than GRAIL. MarketBeat recorded 9 mentions for SELLAS Life Sciences Group and 8 mentions for GRAIL. SELLAS Life Sciences Group's average media sentiment score of 0.62 beat GRAIL's score of 0.60 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SELLAS Life Sciences Group
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
GRAIL
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

SELLAS Life Sciences Group and GRAIL tied by winning 7 of the 14 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Mirum Pharmaceuticals?

SELLAS Life Sciences Group (NASDAQ:SLS) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Mirum Pharmaceuticals had 8 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 17 mentions for Mirum Pharmaceuticals and 9 mentions for SELLAS Life Sciences Group. Mirum Pharmaceuticals' average media sentiment score of 0.64 beat SELLAS Life Sciences Group's score of 0.62 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SELLAS Life Sciences Group
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mirum Pharmaceuticals
7 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Mirum Pharmaceuticals has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A
Mirum Pharmaceuticals$670.78M9.15-$23.36M-$15.47N/A

SELLAS Life Sciences Group has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -134.75%. SELLAS Life Sciences Group's return on equity of -31.95% beat Mirum Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -31.95% -29.86%
Mirum Pharmaceuticals -134.75%-97.25%-12.59%

SELLAS Life Sciences Group has a beta of 2.73, meaning that its share price is 173% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

SELLAS Life Sciences Group presently has a consensus price target of $10.00, suggesting a potential upside of 27.23%. Mirum Pharmaceuticals has a consensus price target of $155.56, suggesting a potential upside of 65.51%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Mirum Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93

Summary

Mirum Pharmaceuticals beats SELLAS Life Sciences Group on 11 of the 16 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Ligand Pharmaceuticals?

SELLAS Life Sciences Group (NASDAQ:SLS) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, Ligand Pharmaceuticals had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 10 mentions for Ligand Pharmaceuticals and 9 mentions for SELLAS Life Sciences Group. Ligand Pharmaceuticals' average media sentiment score of 0.69 beat SELLAS Life Sciences Group's score of 0.62 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SELLAS Life Sciences Group
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ligand Pharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ligand Pharmaceuticals has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A
Ligand Pharmaceuticals$268.09M23.04$124.45M$2.24137.85

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

SELLAS Life Sciences Group presently has a consensus target price of $10.00, suggesting a potential upside of 27.23%. Ligand Pharmaceuticals has a consensus target price of $355.38, suggesting a potential upside of 15.09%. Given SELLAS Life Sciences Group's higher probable upside, equities analysts clearly believe SELLAS Life Sciences Group is more favorable than Ligand Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Ligand Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

Ligand Pharmaceuticals has a net margin of 20.27% compared to SELLAS Life Sciences Group's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 5.22% beat SELLAS Life Sciences Group's return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -31.95% -29.86%
Ligand Pharmaceuticals 20.27%5.22%2.74%

SELLAS Life Sciences Group has a beta of 2.73, suggesting that its stock price is 173% more volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

Summary

Ligand Pharmaceuticals beats SELLAS Life Sciences Group on 13 of the 15 factors compared between the two stocks.

Get SELLAS Life Sciences Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLS vs. The Competition

MetricSELLAS Life Sciences GroupBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.62B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E Ratio-37.3526.5532.9127.37
Price / SalesN/A16.058.595.73
Price / CashN/A26.3721.9322.50
Price / Book16.244.074.403.70
Net Income-$26.86M-$22.86M$3.52B$392.17M
7 Day Performance-12.94%-7.26%-5.34%-4.53%
1 Month Performance-25.15%-4.96%-3.61%-5.86%
1 Year Performance422.38%-2.87%0.01%-7.78%

SELLAS Life Sciences Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLS
SELLAS Life Sciences Group
1.589 of 5 stars
$7.47
-5.0%
$10.00
+33.9%
+449.7%$1.62BN/AN/A13
ORKA
Oruka Therapeutics
2.5702 of 5 stars
$104.56
+1.7%
$133.00
+27.2%
+289.0%$6.71BN/AN/A68
IONS
Ionis Pharmaceuticals
3.5749 of 5 stars
$31.00
-21.4%
$88.29
+184.8%
-59.4%$6.67B$944MN/A1,402
GRAL
GRAIL
2.5318 of 5 stars
$128.08
+5.5%
$121.40
-5.2%
+45.5%$6.42B$147.17MN/A910
MIRM
Mirum Pharmaceuticals
2.8132 of 5 stars
$93.18
-0.6%
$154.94
+66.3%
+31.6%$6.33B$521.31MN/A433

Related Companies and Tools


This page (NASDAQ:SLS) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners